Mechanism of the Blood Pressure-lowering Effect of Sodium-glucose Cotransporter 2 Inhibitors in Obese Patients with Type 2 Diabetes

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2017 Apr 11

PMID 28391776

Citations 36

Authors

Shin Kawasoe

Yukiko Maruguchi

Shoko Kajiya

Hitoshi Uenomachi

Masaaki Miyata

Mariko Kawasoe

Takuro Kubozono

Mitsuru Ohishi

Affiliations

Soon will be listed here.

Abstract

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are reported to have BP-lowering effect in addition to blood glucose-lowering effect, however, its mechanism is still unknown. This study aimed to investigate the mechanism of blood pressure (BP) lowering effects of SGLT2 inhibitors using 24-h urinary collection in obese type 2 diabetes patients.

Methods: Twenty patients with type 2 diabetes (age 48.2 ± 10.7 years, BMI 33.0 ± 4.9 kg/m) were enrolled. Urine volume, 24-h urinary glucose and sodium excretion, and BP at baseline and 2 weeks and 6 months after administration were measured. Body weight, glycosylated hemoglobin, and BP were evaluated before and 1, 3, and 6 months after SGLT2 inhibitor administration. We evaluated the changes in urine volume and urinary excretion of glucose and sodium as well as correlations among urine volume and urinary sodium glucose excretion at 2 weeks and 6 months after administration of the SGLT2 inhibitors. Furthermore, we investigated the correlations between changes in BP and urinary excretion of sodium and glucose at the same time.

Results: Two weeks after administration, systolic BP (SBP) significantly decreased (128.5 ± 11.0 to 123.2 ± 9.8 mmHg, P = 0.0314), but diastolic BP (DBP) did not (74.4 ± 10.4 to 73.4 ± 8.5 mmHg, P = 0.5821). The decreased SBP significantly correlated with increased urinary glucose excretion (R = -0.62, P = 0.0073), but not increased urinary sodium excretion. At 6 months, SBP (118.6 ± 11.0 mmHg, P = 0.0041) and DBP (68.4 mmHg, P = 0.0363) significantly decreased. The decreased SBP significantly correlated with increased urinary sodium excretion (R = -0.60, P = 0.0014), but not increased urinary glucose excretion.

Conclusions: SGLT2 inhibitors significantly decreased SBP after 1 month and DBP after 6 months in obese patients with type 2 diabetes. The main mechanism of the BP-lowering effect may be plasma volume reduction by osmotic diuresis at 2 weeks and by natriuresis at 6 months after SGLT2 inhibitor administration.

Citing Articles

Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes.

Piccirillo F, Lanciotti M, Nusca A, Frau L, Spano A, Liporace P Int J Mol Sci. 2025; 26(5).

PMID: 40076724 PMC: 11899902. DOI: 10.3390/ijms26052103.

Unveiling the benefits of Vitamin D3 with SGLT-2 inhibitors for hypertensive obese obstructive sleep apnea patients.

Loh H, Tay S, Koa A, Yong M, Said A, Chai C J Transl Med. 2025; 23(1):296.

PMID: 40055713 PMC: 11889775. DOI: 10.1186/s12967-025-06312-w.

Diabetes Mellitus and Hyperlipidemia Status Among Hypertensive Patients in the Community and Influencing Factors Analysis of Blood Pressure Control.

Zhang S, Yang Y, Chen X, Fan L, Wu J, Liu X J Clin Hypertens (Greenwich). 2025; 27(2):e14965.

PMID: 39999366 PMC: 11856054. DOI: 10.1111/jch.14965.

Hemodynamic Effects of SGLT2 Inhibitors in Patients with and Without Diabetes Mellitus-A Narrative Review.

Brata R, Pascalau A, Fratila O, Paul I, Muresan M, Camarasan A Healthcare (Basel). 2024; 12(23).

PMID: 39685086 PMC: 11641081. DOI: 10.3390/healthcare12232464.

Chronobiological disruptions: unravelling the interplay of shift work, circadian rhythms, and vascular health in the context of stroke risk.

Li X, He Y, Wang D, Momeni M Clin Exp Med. 2024; 25(1):6.

PMID: 39541048 PMC: 11564290. DOI: 10.1007/s10238-024-01514-w.

References

Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K . Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group.... Cardiovasc Diabetol. 2014; 13:65. PMC: 4021346. DOI: 10.1186/1475-2840-13-65. View

Miyazaki H, Babazono A, Nishi T, Maeda T, Imatoh T, Ichiba M . Does antihypertensive treatment with renin-angiotensin system inhibitors prevent the development of diabetic kidney disease?. BMC Pharmacol Toxicol. 2015; 16:22. PMC: 4567802. DOI: 10.1186/s40360-015-0024-y. View

Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E . Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013; 159(4):262-74. DOI: 10.7326/0003-4819-159-4-201308200-00007. View

Marso S, Daniels G, Brown-Frandsen K, Kristensen P, Mann J, Nauck M . Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375(4):311-22. PMC: 4985288. DOI: 10.1056/NEJMoa1603827. View

Jabbour S, Goldstein B . Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008; 62(8):1279-84. DOI: 10.1111/j.1742-1241.2008.01829.x. View

Ferrannini E, Mark M, Mayoux E . CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016; 39(7):1108-14. DOI: 10.2337/dc16-0330. View

Kushiro T, Kario K, Saito I, Teramukai S, Sato Y, Okuda Y . Increased cardiovascular risk of treated white coat and masked hypertension in patients with diabetes and chronic kidney disease: the HONEST Study. Hypertens Res. 2016; 40(1):87-95. PMC: 5222992. DOI: 10.1038/hr.2016.87. View

Oliva R, Bakris G . Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014; 8(5):330-9. DOI: 10.1016/j.jash.2014.02.003. View

Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A . Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013; 129(5):587-97. DOI: 10.1161/CIRCULATIONAHA.113.005081. View

10.

Weber M, Mansfield T, Cain V, Iqbal N, Parikh S, Ptaszynska A . Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. 2015; 4(3):211-220. DOI: 10.1016/S2213-8587(15)00417-9. View

11.

Ibaraki A, Goto W, Iura R, Tominaga M, Tsuchihashi T . Current prescription status of antihypertensive drugs with special reference to the use of diuretics in Japan. Hypertens Res. 2016; 40(2):203-206. DOI: 10.1038/hr.2016.120. View

12.

Ferrannini E, Cushman W . Diabetes and hypertension: the bad companions. Lancet. 2012; 380(9841):601-10. DOI: 10.1016/S0140-6736(12)60987-8. View

13.

Mather A, Pollock C . Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol. 2010; 6(5):307-11. DOI: 10.1038/nrneph.2010.38. View

14.

Go A, Bauman M, Coleman King S, Fonarow G, Lawrence W, Williams K . An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2013; 63(4):878-85. PMC: 10280688. DOI: 10.1161/HYP.0000000000000003. View

15.

Merovci A, Mari A, Solis-Herrera C, Xiong J, Daniele G, Chavez-Velazquez A . Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab. 2015; 100(5):1927-32. PMC: 4422889. DOI: 10.1210/jc.2014-3472. View

16.

Vykoukal D, Davies M . Vascular biology of metabolic syndrome. J Vasc Surg. 2011; 54(3):819-31. PMC: 3136643. DOI: 10.1016/j.jvs.2011.01.003. View

17.

Campbell N, Gilbert R, Leiter L, Larochelle P, Tobe S, Chockalingam A . Hypertension in people with type 2 diabetes: Update on pharmacologic management. Can Fam Physician. 2011; 57(9):997-1002, e347-53. PMC: 3173417. View

18.

Lambers Heerspink H, de Zeeuw D, Wie L, Leslie B, List J . Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013; 15(9):853-62. PMC: 3906841. DOI: 10.1111/dom.12127. View

19.

Baker W, Smyth L, Riche D, Bourret E, Chamberlin K, White W . Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014; 8(4):262-75.e9. DOI: 10.1016/j.jash.2014.01.007. View

20.

Wanner C, Inzucchi S, Lachin J, Fitchett D, von Eynatten M, Mattheus M . Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016; 375(4):323-34. DOI: 10.1056/NEJMoa1515920. View